Human Genome Epidemiology Literature Finder
|
Records 1 - 10 (of 10 Records) |
| Query Trace: Neoplasms and CES2[original query] |
|---|
| Irinotecan pathway genotype analysis to predict pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Aug 9 (9): 3246-53. Mathijssen Ron H J, Marsh Sharon, Karlsson Mats O, Xie Rujia, Baker Sharyn D, Verweij Jaap, Sparreboom Alex, McLeod Howard |
| Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug metabolism and disposition: the biological fate of chemicals 2007 Oct 35 (10): 1865-72. Kim Su-Ryang, Sai Kimie, Tanaka-Kagawa Toshiko, Jinno Hideto, Ozawa Shogo, Kaniwa Nahoko, Saito Yoshiro, Akasawa Akira, Matsumoto Kenji, Saito Hirohisa, Kamatani Naoyuki, Shirao Kuniaki, Yamamoto Noboru, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Saijo Nagahiro, Sawada Jun-ic |
| Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer chemotherapy and pharmacology 2008 Mar 61 (3): 481-8. Bellott Ricardo, Le Morvan Valérie, Charasson Virginie, Laurand Armelle, Colotte Marthe, Zanger Ulrich M, Klein Kathrin, Smith Denis, Bonnet Jacques, Robert Jacqu |
| Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British journal of cancer 2008 Oct 99 (8): 1239-45. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M, Laurand A, Poirier A-L, Morel A, Chatelut E, Robert J, Gamelin |
| A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Current drug metabolism 2008 May 9 (4): 336-43. Ribelles N, López-Siles J, Sánchez A, González E, Sánchez M J, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba |
| A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Apr 17 (7): 2006-13. Caronia Daniela, Martin Miguel, Sastre Javier, de la Torre Julio, García-Sáenz José Angel, Alonso Maria R, Moreno Leticia T, Pita Guillermo, Díaz-Rubio Eduardo, Benítez Javier, González-Neira An |
| The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer treatment reviews 2016 Nov 50 9-22. Lam S W, Guchelaar H J, Boven |
| Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaar Henk-Jan, Boven Ep |
| Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. British journal of clinical pharmacology 2021 Apr . Ramirez Jacqueline, House Larry K, Ratain Mark |
| Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
- Page last reviewed:Feb 1, 2024
- Content source: